Leading radiosurgery systems maker Accuray Incorporated (ARAY - Analyst Report) said that a leading hospital in Mexico has commenced treating patients with its CyberKnife radiosurgery system, marking the first use of the popular therapy system in that country.
Monterrey-based Christus Muguerza Hospital Alta Especialidad has become the first medical center in Mexico to offer patients the benefits of the CyberKnife system. The hospital, so far, has treated eight patients with malignant tumors or non-cancerous lesions in the brain, head and neck, and kidneys using CyberKnife. The deployment of CyberKnife in Mexico represents a major milestone in the California-based company’s expansion strategy.
CyberKnife, a non-invasive alternative to conventional surgery, is the first and only commercially available intelligent robotic radiosurgery system designed to treat solid tumors anywhere in the body. The device boasts of a technology that differentiates it from traditional treatments.
CyberKnife combines continuous image-guidance technology with a compact linear accelerator that has the ability to move in three dimensions according to the treatment plan. Patients can be treated with the CyberKnife System on an outpatient basis without anesthesia and without the risks and complications inherent in traditional surgery.
Accuray continues to enjoy healthy demand for CyberKnife and is pursuing a number of strategies to boost its adoption. Medical centers across the globe continue to adopt the company’s innovative radiosurgery and radiation therapy systems. Accuray recently stated that the global installation base for its CyberKnife and TomoTherapy systems have crossed 600 across 33 nations in roughly a decade.
Accuray is a global leader in the field of radiosurgery and provides a non-surgical treatment option for patients diagnosed with cancer. More than 200,000 people have been treated with the company’s technology globally.
While Accuray is expected to benefit from the gradual recovery in hospital capital equipment spending, it remains susceptible to reimbursement uncertainties and faces stiff challenges from competitive product offerings of Varian Medical (VAR - Analyst Report). We currently have a Neutral recommendation on Accuray, which is in agreement with a with a short-term Zacks #3 Rank (Hold).